FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

A Blueprint Medicines drug designed to address cancer that carries a certain genetic signature now has FDA approval, the latest targeted therapy to pass the regulatory bar this year.

The late Friday decision for pralsetinib (Gavreto) covers non-small cell lung cancer (NSCLC). The drug was designed to address cancers characterized by fusions or mutations of the RET gene, which produces a protein involved in cell signaling. Genetic abnormalities to the gene drive many types of cancer, including NSCLC. To be eligible for treatment, the RET alterations must first be detected by a genetic test. The drug from Cambridge, MA-based Blueprint... Read more »

Reprints | Share:          

UNDERWRITERS AND PARTNERS

          

          

            
Author: Frank Vinluan

Source : https://xconomy.com/boston/2020/09/05/fda-approves-blueprint-cancer-drug-targeting-ret-genetic-signatures/

Date : 2020-09-05T15:15:08.000Z